Risk willingness in multiple system atrophy and Parkinson’s disease understanding patient preferences

Abstract Disease-modifying therapeutics in the α-synucleinopathies multiple system atrophy (MSA) and Parkinson’s Disease (PD) are in early phases of clinical testing. Involving patients’ preferences including therapy-associated risk willingness in initial stages of therapy development has been incre...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Alexander Maximilian Bernhardt, Marc Oeller, Isabel Friedrich, Emre Kocakavuk, Eliana Nachman, Kevin Peikert, Malte Roderigo, Andreas Rossmann, Tabea Schröter, Lea Olivia Wilhelm, Tino Prell, Christoph van Riesen, Johanna Nieweler, Sabrina Katzdobler, Markus Weiler, Heike Jacobi, Tobias Warnecke, Inga Claus, Carla Palleis, Stephan Breimann, Björn Falkenburger, Moritz Brandt, Andreas Hermann, Jost-Julian Rumpf, Joseph Claßen, Günter Höglinger, Florin Gandor, Johannes Levin, Armin Giese, Annette Janzen, Wolfgang Hermann Oertel
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Nature Portfolio 2024-08-01
Цуврал:	npj Parkinson's Disease
Онлайн хандалт:	https://doi.org/10.1038/s41531-024-00764-5
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!